Describes real-world use of a biomarker panel for disease activity in multiple sclerosis across the United States, highlighting its clinical relevance.
Describe real-world use of the Octave® Multiple Sclerosis Disease Activity (MSDA) Test, a validated blood-based biomarker panel for multiple sclerosis (MS), in US clinical practice.
No takes yet. Share an insight, caveat, or question.
Okuda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: